Metastatic breast cancer patients failing first-line, anthracycline-containing chemotherapy: Is further therapy of benefit?

Anticancer Research

Volumn 19, Issue 4 C, 1999, Pages 3429-3432

  Campora, Elisabetta ^a   Gardin, Giovanni ^b   Gasco, Milena ^a   Rosso, Riccardo ^a   Santi, Leonardo ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Breast cancer; Metastatic disease; Palliation; Systemic treatment

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DIETHYLSTILBESTROL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SURVIVAL; COST BENEFIT ANALYSIS; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; METASTASIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QUALITY OF LIFE; RETROSPECTIVE STUDY; SALVAGE THERAPY; TIME; TREATMENT FAILURE;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; QUALITY OF LIFE; RECURRENCE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TIME FACTORS; TREATMENT FAILURE;

EID: 0033404724     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Micheli A, Verdecchia A, Capocaccia R.- Estimated Incidence and Prevalence of Female Breast Cancer in Italian Regions. Tumori 78: 1321-31, 1992.
2. Consenso sugli Screening in Oncologia: Indirizzo per la Ricerca e Rccomandazione al Servizio Sanitario Nazionale, Tumore della Mammella: Consensus Conference Document of the Consiglio Nazionale delle Ricerche and Associazione Italiana per la Ricerca sul Cancro, Rome, 5-29, June 1996.
3. Landis SH, Murray T, Bolden S, Wingo PA: Cancer Statistics, 1998, CA-Cancer J Clin 48: 6-9, 1998.
4. Todd M, Shoag M, Cadman E: Survival of women with metastatic breast cancer at Yale from 1920 to 1980. J Clin Oncol 1: 406-8, 1983.
5. Clark GM, Sledge GW Jr, Osborne CK, McGuire WL: Survival from first recurrence: relative importance of prognostic factors in 1015 breast cancer patients. J Clin Oncol 5: 55-61, 1987.
6. Sledge GW Jr, Antman KH. Progress in chemotherapy for metastatic breast cancer. Sem Oncol 19: 317-32, 1992.
7. Porkka K, Blomqvist C, Rissanen P, Elomao I, Pyrhonen S. Salvage therapies in women who fail to respond to first-line treatment with Fluorouracil, Epirubicin, and Cyclophosphamide for advanced breast cancer. J Clin Oncol 12: 1639-47, 1994.
8. Conte PF, Pronzato P, Rubagotti A, Alama A, Amadori D, Demicheli R et al: Conventional versus cytokinetic polychemotherapy with estrogenic recruitment in metastatic breast cancer: results of a randomized cooperative trial. J Clin Oncol 5: 839-47, 1987.
9. Conte PF, Gardin G, Pronzato P, Miglietta L, Rosso R, Amadori D et al: In vivo manipulation of human breast cancer growth by estrogens and growth hormone: kinetic and clinical results. J Steroid Biochem Molec Biol 37: 1103-8, 1989.
10. Hayward JL, Carbone PP, Hensen JC. Assessment of response to therapy in advanced breast cancer. Cancer 39: 1289-93, 1977.
11. Gianni L Capri G. Experience at the Istituto Nazionale Tumori with Paclitaxel in combination with doxorubicin in women with untreated breast cancer. Sem Oncol 24: (Suppl 3) S3-1-S3-3, 1997.
12. Smith G, Henderson Cl. New treatments for breast cancer. Sem Oncol 23: 506-28, 1996.
13. Henderson IC, Harris JC: Principles in the management of metastatic disease, In. Harris JR, Hellman S, Henderson Cl, Kinne DW editors. Breast Diseases 2nd ed Philadelphia: Lippincot 547-58, 1991.
14. Cassileth BR, Lusk EJ, DuPont G, Blake AD, Walsh WP, Kascius L et al: Survival and quality of life among patients receiving unproven as compared with conventional cancer therapy. N Engl J Med 324: 1180-85, 1991.
15. Coates A, Gebski V, Bishop JF, Jeal PN, Woods RL, Snyder R et al: Improving the quality of life during chemotherapy for advanced breast cancer. N Engl J Med 317: 1490-95, 1987.
16. Muss HB, Case LD, Richards F II, White DR, Cooper MR, Cruz JM et al: Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. N Engl J Med 325: 1342-48, 1991.
17. Norton L. Metastatic breast cancer. Length and quality of life. N Engl J Med 325: 1370-1, 1991.
18. Osoba D. Lessons learned from measuring health-related quality of life in oncology. J Clin Oncol 12: 608-16, 1994.
19. Stierer M, Rosen HR. Influence of early diagnosis on prognosis of recurrent breast cancer. Cancer 64: 1128-31, 1989.